Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of erlotinib (Tarceva)

Seminars in Oncology

Volumn 30, Issue 3 SUPPL. 7, 2003, Pages 25-33

  Hidalgo, Manuel ^a   Bloedow, Duane ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN P27;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 0038343126     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)70012-8     Document Type: Conference Paper

References (27)

1. Akita RW, Dugger D, Lewis Phillips G, et al: Effects of the EGFR inhibitor Tarceva on activated ErbB2. Proc Am Assoc Cancer Res 43:1003, 2002 (abstr 4973)
2. Pollack VA, Savage DM, Baker DA, et al: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739-748, 1999
3. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
4. Baselga J: New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 18:54S-59S, 2000
5. Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20:2240-2250, 2002
6. Hoekstra R, Dumez H, van Oosterom AT, et al: A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally in a two weeks on, two weeks off scheme to patients with advanced cancer. Proc Am Soc Clin Oncol 21:86a, 2002 (abstr 340)
7. Herbst RS, Maddox AM, Rothenberg ML, et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 20:3815-3825, 2002
8. Baselga J, Rischin D, Ranson M, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302, 2002
9. Giaccone G: A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT I). Ann Oncol 13:2, 2002 (suppl 5) (abstr 4)
10. Johnson D: ZD1839 ('Iressa') in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): Results from a phase III clinical trial (INTACT II). Ann Oncol 13:127, 2002 (suppl 5) (abstr 468)
11. Kelly HC, Ferry D, Hammond L, et al: ZD1839 ("Iressa") an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Pharmacokinetics in a phase 1 study of patients with advanced cancer. Proc Am Assoc Cancer Res 41:612-613, 2000 (abstr 3896)
12. Moyer JD, Barbacci EG, Iwata KK, et al: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838-4848, 1997
13. Rolan PE: Plasma protein binding displacement interactions-Why are they still regarded as clinically important? Br J Clin Pharmacol 37:125-128, 1994
14. Sansom LN, Evans AM: What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf 12:227-233, 1995
15. Benet LZ, Hoener BA: Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115-121, 2002
16. Pérez-Soler R, Chachoua A, Huberman M, et al: A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced-EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:310a, 2001 (abstr 1235)
17. Pérez-Soler R, Chachoua A, Huberman M., et al: Determinants of tumor response and survival in patients with relapsing NSCLC treated with Tarceva (erlotinib HCl; OSI-774). Final report of a phase II study. Presented at the American Society of Clinical Oncology Molecular Therapy Symposium, San Diego, CA, November 8-10, 2002
18. Finkler N, Gordon A, Crozier M, et al: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc Am Soc Clin Oncol 20:208a, 2001 (abstr 831)
19. Hidalgo M: Phase I studies/combination therapy with Tarceva (erlotinib HCl;OSI-774) in head and neck cancer. Presented at the First Annual Opinion Leader Consort on Novel and Targeted Therapies for Head and Neck Cancer, San Juan, Puerto Rico, February 5-9, 2003
20. Senzer NN, Soulieres D, Siu L, et al: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 20:2a, 2001 (abstr 6)
21. Fukouka M, Yano S, Giaccone G, et al: Final results from a phase II trial of ZD1839 ("Iressa" for patients with advanced non-small cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 21:298a, 2002 (abstr 1188)
22. Kies MS, Arquette M, Nabell L, et al: Final report of the efficacy and safety of the anti-epidermal growth factor antibody, cetuximab (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 21:232a, 2002 (abstr 925)
23. Rowinsky E, Schwartz G, Dutcher J, et al: ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFr) monoclonal antibody: Phase II clinical trials in renal cell cancer (RCC). Eur J Cancer 38:57, 2002 (suppl 7) (abstr 178)
24. Saltz L, Rubin M, Hochster H: Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Clin Cancer Res 7:3766, 2001 (suppl) (abstr 559)
25. Malik S, Siu L, Rowinsky E, et al: Pharmacodynamic evaluation of the epidermal growth factor inhibitor OSI-774 (Tarceva) in human epidermis of cancer patients. Clin Cancer Res (in press)
26. Hidalgo M, Malik S, Rowinsky E, et al: Inhibition of the epidermal growth factor receptor (EGFR) by OSI-774, a specific EGFR inhibitor in malignant and normal tissues of cancer patients. Proc Am Soc Clin Oncol 20:71a, 2001 (abstr 281)
27. Albanell J, Rojo F, Averbuch S, et al: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124, 2002